Unravelling DDR Networks by Identifying Novel Targets, Developing Rational Combinations and Improving Biomarker-Lead Clinical Stratification, to Exploit Synthetic Lethality and Deliver Safe
DDR Inhibitors to Patients

The 7th DDR Inhibitors Summit

What the 2024 Summit Uncovered:

DDR inhibitor development is evolving rapidly, marked by the continuous emergence of new targets. AstraZeneca and Merck reaffirm their commitment to DDR inhibitors, yet more pharmaceutical companies like Roche and Gilead are diving into this therapeutic strategy; biotech companies like Artios and IDEAYA remain dedicated to
delivering safe and effective treatments to patients.

The unmet need for cancer therapies reinforces the critical importance for the community that united at the
7th Annual DDR Inhibitors Summit in Boston, January 2024, to advance first-in-class oncology treatments for patients.

This year’s conference underwent a renovation to maximize your experience, featuring a new biomarkers pre-conference focus day with the goal of demystifying patient stratification and target ID. Two tracks for the main conference days followed, covering early discovery of next-generation targets and clinical updates.

100 peers in oncology innovation, synthetic lethality, medicinal chemistry, and clinical development, joined together at the exclusive DDR Inhibitors conference - the sole industry-led event providing unmatched depth and insight into your challenges.

World-Class Speaker Faculty Included:

Eeson Rajendra

Director of DDR Biology

Artios Pharma

Michal Zimmermann

Director of Cancer Biology

Repare Therapeutics

Reeja Maskey

Principal Research Scientist

IDEAYA Biosciences

Matthew Wongchenko

Principal Scientific Manager


Marco Maruggi

Principal Scientist


Mark O’Connor

Chief Scientist - Early Oncology Discovery


Ioannis Gounaris

Head of Clinical Development DDR

Merck KGaA

Jatinder Mukker

Director, Clinical Pharmacology

Merck KGaA

Snapshot of Previously Attending Companies:

Bristol Myers Squibb1
cyrus biotech
Daiichi Sankyo
EMD Serano
FoRx Therapeutics
Sentinel Oncology
Repare Therapeutics
Merck & Co
Zentalis Pharmaceuticals
artios logo
EMD Serano

It was very interactive with many people with different expertise (basic and translational science, clinical, biomarkers, etc.) asking excellent questions of the presenters and panellists.” - Director Oncology Translation & Biomarker Research, EMD Serano

I thought that the quality of the talks was absolutely excellent and that there was a lot of very constructive discussion around future strategies to implement precision medicine. The participation of Pharma was also very important.” - Professor – Cancer Genetics, University of Birmingham

UOB logo

The DDR summit is as usual the place to be for people working in the field of DDR therapeutics, but not only. I enjoyed the quality of speakers and the round tables!” - Head of In Vitro Oncology Research & Innovation, Onxeo

Our 2024 Partners:

Other Events in the Series: